JP2017537928A5 - - Google Patents

Download PDF

Info

Publication number
JP2017537928A5
JP2017537928A5 JP2017529817A JP2017529817A JP2017537928A5 JP 2017537928 A5 JP2017537928 A5 JP 2017537928A5 JP 2017529817 A JP2017529817 A JP 2017529817A JP 2017529817 A JP2017529817 A JP 2017529817A JP 2017537928 A5 JP2017537928 A5 JP 2017537928A5
Authority
JP
Japan
Prior art keywords
syringe
nominal volume
range
nominal
volume
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017529817A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017537928A (ja
JP6726666B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/078482 external-priority patent/WO2016087569A1/en
Publication of JP2017537928A publication Critical patent/JP2017537928A/ja
Publication of JP2017537928A5 publication Critical patent/JP2017537928A5/ja
Application granted granted Critical
Publication of JP6726666B2 publication Critical patent/JP6726666B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017529817A 2014-12-03 2015-12-03 免疫グロブリンを含む安定性が高められた医薬製品 Active JP6726666B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14196069 2014-12-03
EP14196069.0 2014-12-03
PCT/EP2015/078482 WO2016087569A1 (en) 2014-12-03 2015-12-03 Pharmaceutical product with increased stability comprising immunoglobulins

Publications (3)

Publication Number Publication Date
JP2017537928A JP2017537928A (ja) 2017-12-21
JP2017537928A5 true JP2017537928A5 (cg-RX-API-DMAC7.html) 2018-12-27
JP6726666B2 JP6726666B2 (ja) 2020-07-22

Family

ID=52002817

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017529817A Active JP6726666B2 (ja) 2014-12-03 2015-12-03 免疫グロブリンを含む安定性が高められた医薬製品

Country Status (15)

Country Link
US (2) US12144861B2 (cg-RX-API-DMAC7.html)
EP (3) EP3226895B1 (cg-RX-API-DMAC7.html)
JP (1) JP6726666B2 (cg-RX-API-DMAC7.html)
KR (1) KR102745501B1 (cg-RX-API-DMAC7.html)
CN (1) CN106999588A (cg-RX-API-DMAC7.html)
AU (1) AU2015357068B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017010442A2 (cg-RX-API-DMAC7.html)
CA (1) CA2968915A1 (cg-RX-API-DMAC7.html)
DK (2) DK3763384T3 (cg-RX-API-DMAC7.html)
ES (2) ES2825704T3 (cg-RX-API-DMAC7.html)
HU (2) HUE069126T2 (cg-RX-API-DMAC7.html)
MX (1) MX388043B (cg-RX-API-DMAC7.html)
PL (2) PL3226895T3 (cg-RX-API-DMAC7.html)
RU (1) RU2748841C2 (cg-RX-API-DMAC7.html)
WO (1) WO2016087569A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6078344B2 (ja) 2010-02-04 2017-02-08 ツェー・エス・エル・ベーリング・アクチエンゲゼルシャフト 免疫グロブリン製剤
EP2361636A1 (en) * 2010-02-26 2011-08-31 CSL Behring AG Immunoglobulin preparation and storage system for an immunoglobulin preparation
AU2015335743B2 (en) 2014-10-23 2020-12-24 Amgen Inc. Reducing viscosity of pharmaceutical formulations
EP3226895B1 (en) 2014-12-03 2020-07-22 CSL Behring AG Pharmaceutical product with increased stability comprising immunoglobulins
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
TWI865430B (zh) * 2017-07-24 2024-12-11 美商再生元醫藥公司 穩定化之抗體組合物及其製法
CN112119089A (zh) * 2018-05-23 2020-12-22 瑞士杰特贝林生物制品有限公司 Cidp的治疗
US12472162B2 (en) * 2018-07-24 2025-11-18 Carefusion 213, Llc Ready-to-use, terminally sterile packaging for surgical antiseptic and method of use
PT3659594T (pt) * 2018-11-30 2020-12-28 Stegemann Klaus Uma solução estéril com uma seringa de aplicação que contém um agente ativo médico e processo para a sua disponibilização
BR112022001597A2 (pt) 2019-07-29 2022-03-22 Regeneron Pharma Embalagem de dispositivo médico e métodos relacionados
US20220323670A1 (en) * 2021-04-08 2022-10-13 Genixus, Corp. Syringe prefilled with pharmaceutical fluid
WO2023102398A2 (en) * 2021-11-30 2023-06-08 Sab, Llc Ungulate-derived polyclonal immunoglobulin specific for influenza virus and uses thereof
USD1035436S1 (en) 2022-08-26 2024-07-16 Regeneron Pharmaceuticals, Inc. Packaging
USD1042107S1 (en) 2022-08-26 2024-09-17 Regeneron Pharmaceuticals, Inc. Packaging
USD1047700S1 (en) 2022-08-26 2024-10-22 Regeneron Pharmaceuticals, Inc. Packaging
KR20250161658A (ko) 2023-03-29 2025-11-17 체에스엘 베링 아게 부작용과 관련된 면역글로불린을 식별하는 방법

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2364792A1 (de) 1973-01-15 1974-07-18 South African Inventions Verfahren zum reinigen von gammaglobulin
JPS5420124A (en) 1977-07-14 1979-02-15 Green Cross Corp:The Preparation of gamma-globulin intravenous injection
US4186192A (en) 1978-12-18 1980-01-29 Cutter Laboratories, Inc. Stabilized immune serum globulin
US4362661A (en) 1979-08-09 1982-12-07 Teijin Limited Immunoglobulin composition having a high monomer content, and process for production thereof
JPS5731623A (en) 1980-07-30 1982-02-20 Morishita Seiyaku Kk Production of gamma-globulin for intravenous injection
JPS56127321A (en) 1980-03-10 1981-10-06 Mochida Pharmaceut Co Ltd Preparation of gamma-globulin pharmaceutical
JPS56135418A (en) 1980-03-27 1981-10-22 Green Cross Corp:The Heat treatment of aqueous solution containing 8 factor of coagulation of blood derived from human
JPS57128635A (en) 1981-01-30 1982-08-10 Morishita Seiyaku Kk Pharmaceutical preparation of gamma-globulin for venoclysis
US4360451A (en) 1981-08-10 1982-11-23 Basf Wyandotte Corporation Amphoteric surfactant gels
US4499073A (en) 1981-08-24 1985-02-12 Cutter Laboratories, Inc. Intravenously injectable immune serum globulin
US4396608A (en) 1981-08-24 1983-08-02 Cutter Laboratories Intravenously injectable immune serum globulin
US4439421A (en) 1982-08-30 1984-03-27 Baxter Travenol Laboratories, Inc. Stabilized gamma globulin concentrate
JPS6042336A (ja) 1983-08-18 1985-03-06 Nippon Seiyaku Kk 免疫グロブリンの製造方法
JPS60120823A (ja) 1983-12-02 1985-06-28 Green Cross Corp:The IgG単量体
US4597966A (en) 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
JPH0825902B2 (ja) 1985-02-21 1996-03-13 株式会社ミドリ十字 γ−グロブリンの加熱処理方法
JPH0825903B2 (ja) 1985-05-16 1996-03-13 株式会社ミドリ十字 γ―グロブリン含有水溶液
GB8628104D0 (en) 1986-11-25 1986-12-31 Connaught Lab Pasteurization of immunoglobin solutions
DE3641115A1 (de) 1986-12-02 1988-06-16 Lentia Gmbh Verfahren zur herstellung eines intravenoes anwendbaren und in fluessiger form stabilen immunglobulins
ZA902519B (en) 1989-04-04 1991-12-24 Lilly Co Eli Pharmaceutical formulations
JPH0341033A (ja) 1989-07-07 1991-02-21 Kyowa Hakko Kogyo Co Ltd 安定なモチリン類含有製剤
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
ATE122054T1 (de) 1990-03-22 1995-05-15 Biotest Pharma Gmbh Verfahren zur herstellung eines intravenös verträglichen immunglobulin-g-präparates.
JPH04346934A (ja) 1991-05-24 1992-12-02 Green Cross Corp:The γ−グロブリンの液状製剤
DE4118912C1 (cg-RX-API-DMAC7.html) 1991-06-08 1992-07-02 Biotest Pharma Gmbh, 6072 Dreieich, De
DE4126983A1 (de) 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
JP2942412B2 (ja) 1991-12-26 1999-08-30 鐘紡株式会社 化粧料
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
EP0659767B2 (de) 1993-12-27 2002-11-06 ZLB Bioplasma AG Verfahren zur Herstellung eines Konzentrates von Anti-D-Immunoglobulin G und pharmazeutische Zusammensetzung, die dieses enthält
JPH07238036A (ja) 1994-02-28 1995-09-12 Green Cross Corp:The 静注用グロブリン液状組成物のグロブリン二量体増加抑制方法
GB9418092D0 (en) 1994-09-08 1994-10-26 Red Cross Found Cent Lab Blood Organic compounds
JP3765108B2 (ja) 1994-09-30 2006-04-12 三菱ウェルファーマ株式会社 静脈注射用グロブリン製剤
CA2205138A1 (en) 1994-11-16 1996-05-23 Baxter International Inc. Human antibodies to t-cell receptor peptides and methods for their preparation
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
TW491855B (en) 1996-08-07 2002-06-21 Csl Ltd Purification of immunoglobulins
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
BR9714434A (pt) 1996-12-24 2000-05-02 Biogen Inc Formulações de interferon liquidas estáveis
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
KR100632312B1 (ko) 1997-10-23 2007-05-14 미쯔비시 웰 파마 가부시키가이샤 실온저장가능한정맥내주사용면역글로불린제제
US6162904A (en) 1997-12-24 2000-12-19 Alpha Therapeutic Corporation Manufacturing method for intraveneously administrable immune globulin and resultant product
EP2272870B1 (en) 1998-06-09 2013-05-08 CSL Behring AG Process for manufacturing immunoglobulins for intravenous administration and other immunoglobulin-like products
SE0001128D0 (sv) 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
AT410637B (de) * 2001-06-01 2003-06-25 Igeneon Krebs Immuntherapie Verwendung von polyklonalen immunglobulinen
AU2002348148B2 (en) 2001-11-02 2008-07-10 Meridian Medical Technologies, Inc. A medicament container, a medicament dispensing kit for administering medication and a method for packaging the same
WO2004007520A2 (en) * 2002-07-12 2004-01-22 Medarex, Inc. Methods and compositions for preventing oxidative degradation of proteins
US20050142139A1 (en) 2003-03-21 2005-06-30 Norbert Schulke CD4-IgG2 formulations
US20050075611A1 (en) * 2003-10-01 2005-04-07 Hetzler Kevin G. Low extractable, thermoplastic syringe and tip cap
EP1532983A1 (en) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
US20060076536A1 (en) * 2004-09-29 2006-04-13 Barshied Scott R Oxygen scavenging pharmaceutical package and methods for making same
EP1767347A1 (de) * 2005-09-27 2007-03-28 Alcan Technology & Management Ltd. Deckfolie für Blisterverpackungen
US8852167B2 (en) 2005-12-01 2014-10-07 Bayer Medical Care Inc. Medical connector
JP2010504361A (ja) 2006-09-25 2010-02-12 メディミューン,エルエルシー 安定した抗体製剤およびその使用
GB0619060D0 (en) 2006-09-27 2006-11-08 Glaxosmithkline Biolog Sa Novel process
EP2249801A2 (en) * 2008-02-07 2010-11-17 Amgen Inc. Stabilized protein compositions
GB2471726B (en) * 2009-07-10 2013-09-11 Oval Medical Technologies Ltd A pre-filled syringe including an oxygen absorber
CN102655853B (zh) 2009-09-17 2015-07-29 巴克斯特卫生保健有限公司 透明质酸酶和免疫球蛋白的稳定的复合制剂及其使用方法
SG10201604093XA (en) 2010-01-15 2016-07-28 Kirin Amgen Inc Antibody formulation and therapeutic regimens
JP6078344B2 (ja) 2010-02-04 2017-02-08 ツェー・エス・エル・ベーリング・アクチエンゲゼルシャフト 免疫グロブリン製剤
EP2361636A1 (en) * 2010-02-26 2011-08-31 CSL Behring AG Immunoglobulin preparation and storage system for an immunoglobulin preparation
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
WO2012151247A2 (en) * 2011-05-02 2012-11-08 Millennium Pharmaceuticals, Inc. FORMULATION FOR ANTI-α4β7 ANTIBODY
FR2995213A1 (fr) * 2012-09-12 2014-03-14 Lfb Biotechnologies Seringue contenant une composition, notamment pharmaceutique, comprenant des immunoglobulines, son procede de fabrication et son utilisation
EP3424547A1 (en) 2013-03-14 2019-01-09 Fresenius Kabi Austria GmbH Packaging system for oxygen-sensitive drugs
EP3143988A1 (en) 2013-03-14 2017-03-22 Fresenius Kabi Deutschland GmbH Injectable morphine formulations
CN107106409A (zh) * 2014-10-02 2017-08-29 泰尔茂株式会社 用于容纳蛋白质溶液制剂的医疗用容器
EP3226895B1 (en) 2014-12-03 2020-07-22 CSL Behring AG Pharmaceutical product with increased stability comprising immunoglobulins

Similar Documents

Publication Publication Date Title
JP2017537928A5 (cg-RX-API-DMAC7.html)
JP2015503422A5 (cg-RX-API-DMAC7.html)
JP2016028092A5 (cg-RX-API-DMAC7.html)
JP2016065085A5 (cg-RX-API-DMAC7.html)
JP2015053053A5 (cg-RX-API-DMAC7.html)
EA201790630A1 (ru) Способы получения рибозидов
WO2015153889A3 (en) Materials and methods for the treatment of latent viral infection
MA41265A (fr) Compositions pour administration de médicaments iléo-jéjunal.
WO2016011222A3 (en) Circular polynucleotides
JP2016027901A5 (cg-RX-API-DMAC7.html)
JP2016502162A5 (cg-RX-API-DMAC7.html)
JP2014237817A5 (cg-RX-API-DMAC7.html)
TWD173737S (zh) 肌肉鍛鍊機器
LT3390390T (lt) Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui
JP2018533683A5 (cg-RX-API-DMAC7.html)
JP2015186128A5 (cg-RX-API-DMAC7.html)
JP2016540026A5 (cg-RX-API-DMAC7.html)
JP2015173751A5 (cg-RX-API-DMAC7.html)
JP2016540019A5 (cg-RX-API-DMAC7.html)
WO2015138532A3 (en) Methods for the treatment of kidney fibrosis
JP2016038993A5 (cg-RX-API-DMAC7.html)
JP2015016294A5 (cg-RX-API-DMAC7.html)
UY4430S (es) “motocicleta”.
IL257940A (en) Vaccine compositions comprising c-c motif chemokine 22 (ccl22) or fragments thereof
JP2016053220A5 (cg-RX-API-DMAC7.html)